

PubMed

**Format:** Abstract

**Full text links**



*Pharmacol Ther.* 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22.

## Cannabidiol: State of the art and new challenges for therapeutic applications.

Pisanti S<sup>1</sup>, Malfitano AM<sup>2</sup>, Ciaglia E<sup>2</sup>, Lamberti A<sup>2</sup>, Ranieri R<sup>2</sup>, Cuomo G<sup>2</sup>, Abate M<sup>2</sup>, Faggiana G<sup>2</sup>, Proto MC<sup>3</sup>, Fiore D<sup>3</sup>, Laezza C<sup>4</sup>, Bifulco M<sup>5</sup>.

### Author information

### Abstract

Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids.  $\Delta^9$ -THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both compounds have been suggested. However, CBD is recently emerging as a therapeutic agent in numerous pathological conditions since devoid of the psychoactive side effects exhibited instead by  $\Delta^9$ -THC. In this review, we highlight the pharmacological activities of CBD, its cannabinoid receptor-dependent and -independent action, its biological effects focusing on immunomodulation, angiogenetic properties, and modulation of neuronal and cardiovascular function. Furthermore, the therapeutic potential of cannabidiol is also highlighted, in particular in nuerological diseases and cancer.

**KEYWORDS:** Cancer; Cannabidiol; Cannabis; Endocannabinoid system; Neurological diseases

PMID: 28232276 DOI: [10.1016/j.pharmthera.2017.02.041](https://doi.org/10.1016/j.pharmthera.2017.02.041)

[Indexed for MEDLINE]



---

**Publication type, MeSH terms, Substance**

---

**LinkOut - more resources**